CA2657352C - Methods of synthesis and/or purification of diaminophenothiazinium compounds - Google Patents

Methods of synthesis and/or purification of diaminophenothiazinium compounds Download PDF

Info

Publication number
CA2657352C
CA2657352C CA2657352A CA2657352A CA2657352C CA 2657352 C CA2657352 C CA 2657352C CA 2657352 A CA2657352 A CA 2657352A CA 2657352 A CA2657352 A CA 2657352A CA 2657352 C CA2657352 C CA 2657352C
Authority
CA
Canada
Prior art keywords
compound
purifying
precipitate
diaminophenothiazinium
acylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2657352A
Other languages
English (en)
French (fr)
Other versions
CA2657352A1 (en
Inventor
Claude Michel Wischik
John Mervyn David Storey
Colin Marshall
James Peter Sinclair
Thomas Craven Baddeley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38669650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2657352(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CA2657352A1 publication Critical patent/CA2657352A1/en
Application granted granted Critical
Publication of CA2657352C publication Critical patent/CA2657352C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0096—Purification; Precipitation; Filtration
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0097—Dye preparations of special physical nature; Tablets, films, extrusion, microcapsules, sheets, pads, bags with dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2657352A 2006-07-11 2007-07-10 Methods of synthesis and/or purification of diaminophenothiazinium compounds Active CA2657352C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81962706P 2006-07-11 2006-07-11
US60/819,627 2006-07-11
PCT/GB2007/002570 WO2008007074A2 (en) 2006-07-11 2007-07-10 Methods of synthesis and/or purification of diaminophenothiazinium compounds

Publications (2)

Publication Number Publication Date
CA2657352A1 CA2657352A1 (en) 2008-01-17
CA2657352C true CA2657352C (en) 2019-06-11

Family

ID=38669650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2657352A Active CA2657352C (en) 2006-07-11 2007-07-10 Methods of synthesis and/or purification of diaminophenothiazinium compounds

Country Status (16)

Country Link
US (10) US7956183B2 (enExample)
EP (5) EP3121169B1 (enExample)
JP (2) JP5350237B2 (enExample)
CN (2) CN101511803B (enExample)
AU (1) AU2007274057B2 (enExample)
CA (1) CA2657352C (enExample)
CY (1) CY1118184T1 (enExample)
DK (4) DK2457904T3 (enExample)
ES (4) ES2912571T3 (enExample)
HU (1) HUE030621T2 (enExample)
LT (1) LT2457905T (enExample)
MY (2) MY148145A (enExample)
PL (4) PL2457904T3 (enExample)
PT (4) PT2457904E (enExample)
SI (4) SI2457905T1 (enExample)
WO (1) WO2008007074A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2409683T3 (es) 2004-09-23 2013-06-27 Wista Laboratories Ltd. Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN101511803B (zh) * 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
FR2903696B1 (fr) * 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
PL2167095T3 (pl) * 2007-06-19 2019-11-29 Wista Lab Ltd Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych
DK2205245T3 (en) * 2007-10-03 2015-09-28 Wista Lab Ltd Therapeutic use of diaminophenothiaziner
KR101774598B1 (ko) * 2008-12-09 2017-09-04 인터퀴임, 에스.에이. （6ｓ）­（­）­５，６，７，８­테트라하이드로-６-［프로필­（２­티에닐）에틸］아미노­１­나프톨（로티고틴）의 제조를 위한 공정
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
RU2535073C1 (ru) * 2013-07-18 2014-12-10 Федеральное государственное бюджетное учреждение науки "Научно-исследовательский институт общей реаниматологии имени В.А. Неговского" Российской академии медицинских наук Способ лечения метгемоглобинемии
DK3033331T3 (da) 2013-08-15 2018-04-30 Eupharma Pty Ltd Fremgangsmåde til oprensning af diaminophenothiazinium forbindelser
GB201317702D0 (en) * 2013-10-07 2013-11-20 Wista Lab Ltd Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
FR3015481B1 (fr) * 2013-12-20 2016-08-12 Etat Francais Represente Par Le Delegue General Pour L'armement Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite
CN103864717B (zh) * 2014-04-04 2015-11-11 山东理工大学 一种针状亚甲基白晶体的制备方法
CA2976937C (en) 2015-02-17 2023-04-04 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
DK3258938T3 (da) 2015-02-17 2021-02-01 Univ Arizona State Phenothiazinanaloger som mitokondrie terapeutiske midler
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105399703B (zh) * 2015-12-15 2018-02-13 江苏恒润制药有限公司 一种亚甲基蓝的制备方法
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
ITUA20163526A1 (it) * 2016-05-17 2017-11-17 Icrom Spa Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza
PT3487505T (pt) 2016-07-25 2023-06-07 Wista Lab Ltd Administração e dosagem de diaminofenotiazinas
US12570622B2 (en) 2016-08-25 2026-03-10 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10745366B2 (en) 2016-08-25 2020-08-18 Arizon Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
US11413240B2 (en) 2016-12-29 2022-08-16 Board Of Regents, The University Of Texas System Methylene blue solution for the treatment of oral lesions
US10584201B2 (en) * 2017-01-10 2020-03-10 The Texas A&M University System Methanesulfonic acid mediated solvent free synthesis of conjugated porous polymer networks
FR3063495B1 (fr) * 2017-03-02 2019-04-05 Provepharm Life Solutions Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium
EP3375777A1 (en) 2017-03-15 2018-09-19 MIKROCHEM spol. s.r.o. Method for preparation of 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride or bromide
JP7465861B2 (ja) 2018-07-26 2024-04-11 ウィスタ ラボラトリーズ リミテッド 集団におけるジアミノフェノチアジンの最適化投与
US11350853B2 (en) 2018-10-02 2022-06-07 Under Armour, Inc. Gait coaching in fitness tracking systems
CN109337681B (zh) * 2018-11-22 2020-05-08 南京工业大学 一种硫氮共掺杂的碳量子点的制备方法和应用
TR201818670A2 (tr) 2018-12-05 2020-06-22 Eti Gida Sanayi Ve Ticaret Anonim Sirketi Sızıntı yapmayan gıda dolgu maddesi depozitör sistemi.
US12215234B2 (en) * 2019-09-21 2025-02-04 RK Pharma Solutions LLC Process for the purification of methylene blue
AU2021226188A1 (en) * 2020-02-28 2022-11-10 Dishman Carbogen Amcis Ltd A process for the preparation of methylene blue
US12280062B2 (en) 2021-02-24 2025-04-22 Zydus Lifesciences Limited Parenteral compositions comprising methylene blue
CN114656424B (zh) * 2022-03-16 2023-06-27 深圳先进技术研究院 一种上转换长余辉化学发光成像纳米探针及其制备方法和应用
CN114806211B (zh) * 2022-03-16 2023-04-07 深圳先进技术研究院 一种疏水性亚甲蓝荧光染料及其制备方法和应用
CN114507193B (zh) * 2022-04-19 2022-06-24 英科隆生物技术（杭州）有限公司 电子媒介体天青c的提纯方法
CN116947783B (zh) * 2022-04-19 2026-04-17 英科隆生物技术（杭州）有限公司 一种电子媒介体的提纯方法
WO2023202464A1 (zh) * 2022-04-19 2023-10-26 英科隆生物技术（杭州）有限公司 一种电子媒介体的提纯方法
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
CN114989113A (zh) * 2022-06-01 2022-09-02 山东科源制药股份有限公司 一种药用亚甲基蓝的精制方法
EP4590275A1 (en) 2022-09-21 2025-07-30 WisTa Laboratories Ltd. Novel formulations and vehicles
EP4342451A1 (en) 2022-09-22 2024-03-27 Galenicum Health SLU Pharmaceutical compositions and manufacturing methods thereof
US20240115579A1 (en) 2022-09-22 2024-04-11 Galenicum Health S.L.U. Pharmaceutical compositions and manufacturing methods thereof
CN117447421A (zh) * 2023-10-30 2024-01-26 上海沃凯生物技术有限公司 一种3,7-双-（二甲胺基）-吩噻嗪的合成方法
IT202400006715A1 (it) * 2024-03-26 2025-09-26 Icrom S R L Blu di metilene a ridotto contenuto di impurità n-nitroso-azzurro b e processo per ottenerlo
CN119823064B (zh) * 2025-01-03 2025-12-30 仁合益康集团有限公司 一种亚甲蓝的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1886C (de) 1877-12-15 1877-12-15 Basf Ag Verfahren zur darstellung blauer farbstoffe aus dimethylanilin und anderen tertiaeren aromatischen monaminen
DE103147C (de) 1898-06-07 1899-04-05 Cohn Georg Verfahren zur darstellung von acetylleukomethylenblau und -äthylenblau.
DE113721C (de) * 1899-06-01 1900-09-28 Verfahren zur Darstellung von Acidylderivaten der Leukothioninfarbstoffe
US3395018A (en) 1964-04-29 1968-07-30 Du Pont Light-sensitive color-forming composition
US3641016A (en) * 1968-02-16 1972-02-08 Egyt Gyogyszervegyeszeti Gyar Thionine derivatives
DE2515966C3 (de) 1975-04-11 1979-11-22 Boehringer Mannheim Gmbh, 6800 Mannheim Vorgefärbte Objektträger für die Blutunte rsuchung
US4003892A (en) 1975-04-17 1977-01-18 Serva-Entwicklungslabor V. Grothe & Co. Method of separating thionine and its N-methyl derivatives from each other
US4212971A (en) 1979-03-08 1980-07-15 American Cyanamid Company Process for preparing methylene blue
JPS6385644A (ja) * 1986-09-30 1988-04-16 Ricoh Co Ltd 電子写真現像剤用トナ−
US5344928A (en) 1991-04-26 1994-09-06 Takeda Chemical Industries, Ltd. Phenothiazine derivatives, their production and use
US6238931B1 (en) * 1993-09-24 2001-05-29 Biosite Diagnostics, Inc. Fluorescence energy transfer in particles
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
EP0973383A4 (en) 1997-01-21 2001-08-22 American Nat Red Cross INTRACELLULAR AND EXTRACELLULAR DECONTAMINATION OF WHOLE BLOOD AND BLOOD COMPONENTS WITH AMPHIPHILEN PHENOTHIAZINE-5-IUM DYES AND LIGHT
JP2000344685A (ja) 1999-03-26 2000-12-12 Bf Kenkyusho:Kk アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
IT1307270B1 (it) 1999-10-12 2001-10-30 Dideco Spa Procedimento e dispositivo per la determinazione della concentrazionedi eparina in un campione di fluido.
JP2003531828A (ja) * 2000-02-26 2003-10-28 アドバンスト フォトダイナミック テクノロジーズ， インコーポレイテッド 光感光性物質および界面活性剤を使用する、光力学的な細胞および無細胞生物の根絶
FR2810318B1 (fr) 2000-06-15 2005-09-23 Laurent Galey Derives de diamano-phenothiazine
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB2373787A (en) 2001-03-08 2002-10-02 Univ Central Lancashire Phenothiazinium derivatives and their use to reduce pathogenic contaminants
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
US7176308B2 (en) * 2002-06-17 2007-02-13 Verification Technologies, Inc. Processes for preparing novel methylene blue derivative
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
AU2004295148A1 (en) * 2003-11-28 2005-06-16 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
ES2409683T3 (es) 2004-09-23 2013-06-27 Wista Laboratories Ltd. Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN101511803B (zh) 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
FR2903696B1 (fr) * 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
PT3487505T (pt) 2016-07-25 2023-06-07 Wista Lab Ltd Administração e dosagem de diaminofenotiazinas
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
JP7465861B2 (ja) 2018-07-26 2024-04-11 ウィスタ ラボラトリーズ リミテッド 集団におけるジアミノフェノチアジンの最適化投与
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies

Also Published As

Publication number Publication date
CA2657352A1 (en) 2008-01-17
CN101511803A (zh) 2009-08-19
MY148145A (en) 2013-03-15
JP6243659B2 (ja) 2017-12-06
EP2457905A1 (en) 2012-05-30
SI2457904T1 (sl) 2015-02-27
US20250222006A1 (en) 2025-07-10
US9980971B2 (en) 2018-05-29
AU2007274057A1 (en) 2008-01-17
CN102718730B (zh) 2018-06-05
US11045477B2 (en) 2021-06-29
US11878021B2 (en) 2024-01-23
PT2457904E (pt) 2015-02-27
WO2008007074A3 (en) 2008-02-28
US20240115580A1 (en) 2024-04-11
LT2457905T (lt) 2016-11-10
SI2457905T1 (sl) 2016-12-30
US20130317012A1 (en) 2013-11-28
EP2057136A2 (en) 2009-05-13
PL3121169T3 (pl) 2022-05-23
EP2457904B1 (en) 2014-11-19
US20160296531A1 (en) 2016-10-13
ES2912571T3 (es) 2022-05-26
PL2057136T3 (pl) 2013-10-31
JP2013253095A (ja) 2013-12-19
EP4063354A1 (en) 2022-09-28
EP2457904A1 (en) 2012-05-30
DK3121169T3 (da) 2022-02-28
JP2009542786A (ja) 2009-12-03
DK2457905T3 (en) 2016-11-28
US20170273986A1 (en) 2017-09-28
PT2057136E (pt) 2013-08-28
PL2457904T3 (pl) 2015-04-30
US20090259040A1 (en) 2009-10-15
PL2457905T3 (pl) 2017-02-28
DK2457904T3 (en) 2015-01-12
US10525061B2 (en) 2020-01-07
EP2057136B1 (en) 2013-05-22
US7956183B2 (en) 2011-06-07
HUE030621T2 (en) 2017-05-29
US20200261465A1 (en) 2020-08-20
MY162313A (en) 2017-05-31
HK1129675A1 (en) 2009-12-04
EP3121169A1 (en) 2017-01-25
AU2007274057B2 (en) 2012-12-13
ES2529714T3 (es) 2015-02-24
JP5350237B2 (ja) 2013-11-27
CN102718730A (zh) 2012-10-10
EP2457905B1 (en) 2016-08-17
US9675621B2 (en) 2017-06-13
PT3121169T (pt) 2022-05-13
PT2457905T (pt) 2016-11-24
SI2057136T1 (sl) 2013-09-30
WO2008007074A2 (en) 2008-01-17
US20180263999A1 (en) 2018-09-20
US20110294795A1 (en) 2011-12-01
DK2057136T3 (da) 2013-08-26
ES2603783T3 (es) 2017-03-01
CY1118184T1 (el) 2017-06-28
US20210322435A1 (en) 2021-10-21
US8440821B2 (en) 2013-05-14
US9382220B2 (en) 2016-07-05
ES2421930T3 (es) 2013-09-06
CN101511803B (zh) 2012-10-31
SI3121169T1 (sl) 2022-05-31
EP3121169B1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US11878021B2 (en) Methods of synthesis and/or purification of diaminophenothiazinium compounds
AU2013200264B2 (en) Methods of synthesis and/or purification of diaminophenothiazinium compounds
HK1233267A1 (en) Methods of synthesis and/or purification of diaminophenothiazinium compounds
HK1233267B (en) Methods of synthesis and/or purification of diaminophenothiazinium compounds
HK1129675B (en) Methods of synthesis and/or purification of diaminophenothiazinium compounds

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250630

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250630